The human papillomavirus 16 E6 protein can either protect or further sensitize cells to TNF: Effect of dose

Cell Death and Differentiation

Volumn 12, Issue 12, 2005, Pages 1622-1635

  Filippova, M ^a   Brown Bryan, T A ^a   Casiano, C A ^a   Duerksen Hughes, P J ^a  

^a LOMA LINDA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Apoptosis; Caspase activation; Dose dependence; E6; HPV 16; TNF

Indexed keywords

CELL PROTEIN; DOXYCYCLINE; PROTEIN E6; TUMOR NECROSIS FACTOR;

APOPTOSIS; ARTICLE; CELL CLONE; CELL LINE; CELL PROTECTION; CONTROLLED STUDY; GENE ACTIVITY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; IMMUNE RESPONSE; ONCOGENE; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; SENSITIZATION; UTERINE CERVIX CARCINOMA; VIRUS CELL INTERACTION; VIRUS STRAIN;

APOPTOSIS; CASPASES; CELL LINE, TUMOR; DOXYCYCLINE; ENZYME ACTIVATION; HUMANS; ONCOGENE PROTEINS, VIRAL; REPRESSOR PROTEINS; TUMOR NECROSIS FACTORS; TUMOR SUPPRESSOR PROTEIN P53;

HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPE 16;

EID: 27944454386     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/sj.cdd.4401678     Document Type: Article

References (82)

1. Howley PM, Munger K, Romanczuk H, Scheffner M and Huibregtse JM (1992) Cellular Targets of the Oncoproteins Encoded by the Cancer Associated Human Papillomaviruses (Boca Raton, FL: CRC Press; Japan Sci. Soc. Press: Tokyo) pp. 239-248
2. Scheffner M, Werness BA, Huibregtse JM, Levine AJ and Howley PM (1990) The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63: 1129-1136
3. Patel D, Huang SM, Baglia LA and McCance DJ (1999) The E6 protein of human papillomavirus type 16 binds to and inhibits co-activation by CBP and p300. EMBO J. 18: 5061-5072
4. Zimmermann H, Degenkolbe R, Bernard H and O'Connor M (1999) The human papillomavirus type 16 E6 oncoprotein can down-regulate p53 activity by targeting the transcriptional coactivator CBP/p300. J. Virol. 73: 6209-6219
5. Ronco LV, Karpova AY, Vidal M and Howley PM (1998) Human papillomavirus 16 E6 oncoprotein binds to interferon regulatory factor-3 and inhibits its transcriptional activity. Genes Dev. 12: 2061-2072
6. Kukimoto I, Aihara S, Yoshiike K and Kanda T (1998) Human papillomavirus oncoprotein E6 binds to the C-terminal region of human minichromosome maintenance 7 protein. Biochem. Biophys. Res. Commun. 249: 258-262
7. Kuhne C and Banks L (1998) E3-ubiquitin ligase/E6-AP links multicopy maintenance protein 7 to the ubiquitination pathway by a novel motif, the L2G box. J. Biol. Chem. 273: 34302-34309
8. Gao Q, Srinivasan S, Boyer SN, Wazer DE and Band V (1999) The E6 oncoproteins of high-risk papillomaviruses bind to a novel putative GAP protein, E6TP1, and target it for degradation. Mol. Cell. Biol. 19: 733-744
9. Zeng M, Kumar A, Meng G, Gao Q, Dimri G, Wazer DE, Band H and Band V (2002) Human papillomavirus 16 E6 oncoprotein inhibits retinoic X receptor-mediated transactivation by targeting human ADA3 coactivator. J. Biol. Chem. 277: 45611-45618
10. Kumar A, Zhao Y, Meng G, Zeng M, Srinivasan S, Delmolino LM, Gao Q, Dimri G, Weber GF, Wazer DE, Band H and Band V (2002) Human papillomavirus oncoprotein E6 inactivates the transcriptional coactivator human ADA3. Mol. Cell. Biol. 22: 5801-5812
11. Gupta S, Takhar PP, Degenkolbe R, Koh CH, Zimmermann H, Yang CM, Guan Sim K, Hsu SI and Bernard HU (2003) The human papillomavirus type 11 and 16 E6 proteins modulate the cell-cycle regulator and transcription cofactor TRIP-Br1. Virology 317: 155-164
12. Lu Z, Hu X, Li Y, Zheng L, Zhou Y, Jiang H, Ning T, Basang Z, Zhang C and Ke Y (2004) Human papillomavirus 16 E6 oncoprotein interferences with insulin signaling pathway by binding to tuberin. J. Biol. Chem. 279: 35664-35670
13. Thomas M and Banks L (1998) Inhibition of Bak-induced apoptosis by HPV-18 E6. Oncogene 17: 2943-2954
14. Veldman T, Liu X, Yuan H and Schlegal R (2003) Human papillomavirus E6 and Myc proteins associate in vivo and bind to and cooperatively activate the telomerase reverse transcriptase promoter. Proc. Natl. Acad. Sci. USA 100: 8211-8216
15. Tross-Mesilaty S, Reinstein E, Bercovich B, Tobias KE, Schwartz AL, Kahana C and Ciechanover A (1998) Basal and human papillomavirus E6 oncoprotein-induced degradation of Myc proteins by the ubiquitin pathway. Proc. Natl. Acad. Sci. USA 95: 8058-8063
16. Filippova M, Song H, Connolly JL, Dermody TS and Duerksen-Hughes PJ (2002) The human papillomavirus 16 E6 protein binds to Tumor Necrosis Factor (TNF) R1 and protects cells from TNF-induced apoptosis. J. Biol. Chem. 277: 21730-21739
17. Filippova M, Parkhurst L and Duerksen-Hughes PJ (2004) The human papillomavirus 16 E6 protein binds to Fas-Associated Death Domain and protects cells from Fas-triggered apoptosis. J. Biol. Chem. 279: 25729-25744
18. Tong X and Howley PM (1997) The bovine papillomavirus E6 oncoprotein interacts with paxillin and disrupts the actin cytoskeleton. Proc. Natl. Acad. Sci. USA 94: 4412-4417
19. Chen JJ, Reid CE, Band V and Androphy EJ (1995) Interaction of papillomavirus E6 oncoproteins with a putative calcium-binding protein. Science 269: 529-531
20. Degenhardt YY and Silverstein S (2001) Interaction of zyxin, a focal adhesion protein, with the E6 protein from human papillomavirus type 6 results in its nuclear translocation. J. Virol. 23: 11791-11802
21. Du M, Fan X, Hong E and Chen JJ (2002) Interaction of oncogenic papillomavirus E6 proteins with fibulin-1. Biochem. Biophys. Res. Commun. 296: 962-969
22. Kiyono T, Hiraiwa A, Fujita M, Hayashi Y, Akiyama T and Ishibashi M (1997) Binding of high-risk human papillomavirus E6 oncoproteins to the human homologue of the Drosophila discs large tumor suppressor protein. Proc. Natl. Acad. Sci. USA 94: 11612-11616
23. Lee SS, Weiss RS and Javier RT (1997) Binding of human virus oncoproteins to hDlg/SAP97, a mammalian homolog of the Drosophila disks large tumor suppressor protein. Proc. Natl. Acad. Sci. USA 94: 6670-6675
24. Nakagawa S and Huibregtse JM (2000) Human scribble (Vartul) is targeted for ubiquitin-mediated degradation by the high-risk papillomavirus E6 proteins and the E6AP ubiquitin-protein ligase. Mol. Cell. Biol. 20: 8244-8253
25. Thomas M, Glausinger BA, Pim D, Javier RT and Banks L (2001) HPV E6 and MAGUK protein interactions: Determination of the molecular basis for specific protein recognition and degradation. Oncogene 20: 5431-5439
26. Glausinger BA, Lee SS, Thomas M, Banks L and Javier RT (2000) Interactions of the PDZ-protein MAGI-1 with adenovirus E4-ORF1 and high-risk papillomavirus E6 oncoproteins. Oncogene 19: 5270-5280
27. Thomas M, Laura R, Hepner K, Guccione E, Sawyers C, Lasky L and Banks L (2002) Oncogenic human papillomavirus E6 proteins target the MAGI-2 and MAGI-3 proteins for degradation. Oncogene 21: 5088-5096
28. Lee SS, Glausinger BA, Mantovani F, Banks L and Javier RT (2000) Multi-PDZ domain protein MUPP1 is a cellular target for both adenovirus E4-ORF1 and high-risk papillomavirus type 18 E6 oncoproteins. J. Virol. 74: 9680-9693
29. Iftner T, Ebel M, Schopp B, Hiler T, Loizou JI, Caldecott KW and Stubrenrauch F (2002) Interference of papillomavirus E6 protein with single-strand break repair by interaction with XRCC1. EMBO J. 21: 47141-47148
30. Srivenugopal KS and Ali-Osman F (2002) The DNA repair protein, O(6)-methylguanine-DNA methyltransferase is a proteolytic target for the E6 human papillomavirus oncoprotein. Oncogene 21: 5940-5945
31. Benedict CA, Banks TA and Ware CF (2003) Death and survival: Viral regulation of TNF signaling pathways. Curr. Opin. Immunol. 15: 59-65
32. Benedict CA (2003) Viruses and the TNF-related cytokines, an evolving battle. Cytokine Growth Factors Rev. 14: 349-357
33. Finzer P, Aguilar-Lemarroy A and Rosl F (2002) The role of human papillomavirus oncoproteins E6 and E7 in apoptosis. Cancer Lett. 188: 15-24
34. Vikhanskaya F, Falugi C, Valente P and Russo P (2002) Human papillomavirus type 16 E6-enhanced susceptibility to apoptosis induced by TNF in A2780 human ovarian cancer cell line. Int. J. Cancer 97: 732-739
35. Liu Y, Tergaonkar V, Krishna S and Androphy EJ (1999) Human papillomavirus type 16 E6-enhanced susceptibility of L929 cells to tumor necrosis factor alpha correlates with increased accumulation of reactive oxygen species. J. Biol. Chem. 274: 24819-24827
36. Duerksen-Hughes PJ, Yang J and Schwartz SB (1999) HPV 16 E6 blocks TNF-mediated apoptosis in mouse fibroblast LM cells. Virology 264: 55-65
37. ATCC (2005) CRL-1550, HTB-35; http://www.atcc.org.
38. Yang J and Duerksen-Hughes PJ (1998) A new approach to identifying genotoxic carcinogens: P53 induction as an indicator of genotoxic damage. Carcinogenesis 19: 1117-1125
39. Luschen S, Ussat S, Scherer G, Kabelitz D and Adam-Klages S (2000) Sensitization to death receptor cytotoxicity by inhibition of fas-associated death domain protein (FADD)/caspase signaling. Requirement of cell cycle progression. J. Biol. Chem. 275: 24670-24678
40. Vercammen D, Beyaert R, Denecker G, Goossens V, Van Loo G, Declercq W, Grooten J, Fiers W and Vandenabeele P (1998) Inhibition of caspases increases the sensitivity of L929 cells to necrosis mediated by tumor necrosis factor. J. Exp. Med. 187: 1477-1485
41. Casiano CA, Martin SJ, Green DR and Tan EM (1996) Selective cleavage of nuclear autoantigens during CD95 (Fas/APO-1)-mediated T cell apoptosis. J. Exp. Med. 184: 765-770
42. Casiano CA, Ochs RL and Tan EM (1998) Distinct cleavage products of nuclear proteins in apoptosis and necrosis revealed by autoantibody probes. Cell Death Differ. 5: 183-190
43. Wu X, Molinaro C, Johnson N and Casiano CA (2001) Secondary necrosis is a source of proteolytically modified forms of specific intracellular autoantigens: Implications for systemic autoimmunity. Arthritis Rheum. 44: 2642-2652
44. Scaffidi C, Schmitz I, Zha J, Korsmeyer SJ, Krammer PH and Peter ME (1999) Differential modulation of apoptosis sensitivity in CD95 type I and type II cells. J. Biol. Chem. 274: 22532-22538
45. Scaffidi C, Fulda S, Srinivasan A, Friesen C, Li F, Tomaselli KJ, Debatin KM, Krammer PH and Peter ME (1998) Two CD95 (APO-1/Fas) signaling pathways. EMBO J. 17: 1675-1687
46. Seaton TA, Cooper JM and Schapira AH (1998) Cyclosporin inhibition of apoptosis induced by mitochondrial complex I toxins. Brain Res. 809: 12-17
47. Zamzami N, Marchetti P, Castedo M, Hirsch T, Susin SA, Masse B and Kroemer G (1996) Inhibitors of permeability transition interfere with the disruption of the mitochondrial transmembrane potential during apoptosis. FEBS Lett. 384: 53-57
48. Friberg H, Ferrand-Drake M, Bengtsson F, Halestrap AP and Wieloch T (1998) Cyclosporin A, but not FK 506, protects mitochondria and neurons against hypoglycemic damage and implicates the mitochondrial permeability transition in cell death. J. Neurosci. 18: 5151-5159
49. Walter DH, Haendeler J, Galle J, Zeiher AM and Dimmeler S (1998) Cyclosporin A inhibits apoptosis of human endothelial cells by preventing release of cytochrome C from mitochondria. Circulation 98: 1153-1157
50. Baines CP, Kaiser RA, Purcell NH, Blair NS, Osinska H, Hambleton MA, Brunskill EW, Sayen MR, Gottlieb RA, Dorn GWI, Robbins J and Molkentin JD (2005) Loss of cyclophilin D reveals a critical role for mitochondrial permeability transition in cell death. Nature 434: 658-662
51. Nakagawa T, Shimizu S, Watanabe T, Yamaguchi O, Otsu K, Yamagata H, Inohara H, Kubo T and Tsujimoto Y (2005) Cyclophilin D-dependent mitochondrial permeability transition regulates some necrotic but not apoptotic cell death. Nature 434: 652-658
52. Yang J and Duerksen-Hughes PJ (2001) Activation of a p53-independent, sphingolipid-mediated cytotolytic pathway in p53-negative mouse fibroblast cells treated with N-methyl-N-nitro-N-nitrosoguanidine. J. Biol. Chem. 276: 27129-27135
53. Obeid LM, Linardic CM, Karolak LA and Hannun YA (1993) Programmed cell death induced by ceramide. Science 259: 1769-1771
54. Benedict CA and Ware CF (2001) Virus targeting of the tumor necrosis superfamily. Virology 289: 1-5
55. Hay S and Kannourakis G (2002) A time to kill: Viral manipulation of the cell death program. J. Gen. Virol. 83: 1547-1564
56. Tortorella D, Gewurz BE, Furman MH, Schust DJ and Ploegh HL (2000) Viral subversion of the immune system. Annu. Rev. Immunol. 18: 861-926
57. Benedict CA, Norris PS and Ware CF (2002) To kill or be killed: Viral evasion of apoptosis. Nat. Immunol. 3: 1013-1018
58. Shisler J, Duerksen-Hughes PJ, Hermiston TM, Wold WS and Gooding LR (1996) Induction of susceptibility to tumor necrosis factor by E1A is dependent on binding to either p300 or p105-Rb and induction of DNA synthesis. J. Virol. 70: 68-77
59. Morrison TE, Mauser A, Klingelhutz A and Kenney SC (2004) Epstein-Barr virus immediate-early protein BZLF1 inhibits tumor necrosis factor alpha-induced signaling and apoptosis by downregulating tumor necrosis factor receptor 1. J. Virol. 78: 544-549
60. Kieser A, Kaiser C and Hammerschmidt W (1999) LMP1 signal transduction differs substantially from TNF receptor 1 signaling in the molecular functions of TRADD and TRAF2. EMBO J. 18: 2511-2521
61. Baillie J, Sahlender DA and Sinclair JH (2003) Human cytomegalovirus infection inhibits tumor necrosis factor alpha (TNF-α) signaling by targeting the 55-kilodalton TNF-α receptor. J. Virol. 77: 7007-7016
62. Bertin J, Armstrong RC, Ottilie S, Martin DA, Wang Y, Banks S, Wang G-H, Senkevich TG, Alnemri ES, Moss B, Lenardo MJ, Tomaselli KJ and Cohen JI (1997) Death effector domain-containing herpesvirus and poxvirus proteins inhibit both Fas- and TNFR1-induced apoptosis. Proc. Natl. Acad. Sci. USA 94: 1172-1176
63. Garvey TL, Bertin J, Siegel RM, Wang G-H, Lenardo MJ and Cohen JI (2002) Binding of FADD and caspase-8 to Molluscum Contagiosum virus MC159 v-FLIP is not sufficient for its antiapoptotic function. J. Virol. 76: 697-706
64. Hu S, Vincenz C, Buller M and Dixit VM (1997) A novel family of viral death effector domain-containing molecules that inhibit both CD95 and tumor necrosis factor receptor 1-induced apoptosis. J. Biol. Chem. 272: 9621-9624
65. Stenner-Liewen F, Liewen H, Zapata JM, Pawlowski K, Godzik A and Reed JC (2002) CADD, a Chlamydia protein that interacts with death receptors. J. Biol. Chem. 277: 9633-9636
66. Longworth MS and Laimins LA (2004) Pathogenesis of human papillomaviruses in differentiating epithelia. Microbiol. Mol. Biol. Rev. 68: 362-372
67. Malejczyk J, Malejczyk M, Kock A, Urbanski A, Majewski S, Hunzelmann N, Jablonska S, Orth G and Luger TA (1992) Autocrine growth limitation of human papillomavirus type 16-harboring keratinocytes by constitutively released tumor necrosis factor-alpha. J. Immunol. 149: 2702-2708
68. Delvenne P, al-Saleh W, Gilles C, Thiry A and Boniver J (1995) Inhibition of growth of normal and human papillomavirus-transformed keratinocytes in monolayer and organotypic cultures by interferon-gamma and tumor necrosis factor-alpha. Am. J. Pathol. 146: 589-598
69. Villa LL, Vieira KB, Pei XF and Schlegel R (1992) Differential effect of tumor necrosis factor on proliferation of primary human keratinocytes and cell lines containing human papillomavirus types 16 and 18. Mol. Carcinog. 6: 5-9
70. Basile JR, Zacny V and Munger K (2001) The cytokines tumor necrosis factor-alpha (TNF-alpha) and TNF-related apoptosis-inducing ligand differentially modulate proliferation and apoptotic pathways in human keratinocytes expressing the human papillomavirus-16 E7 oncoprotein. J. Biol. Chem. 276: 22522-22528
71. Boccardo E, Noya F, Broker TR, Chow LT and Villa LL (2004) HPV-18 confers resistance to TNF-alpha in organotypic cultures of human keratinocytes. Virology 328: 233-243
72. Thompson DA, Zacny V, Belinsky GS, Classon M, Jones DL, Schlegel R and Munger K (2001) The HPV E7 oncoprotein inhibits tumor necrosis factor alpha-mediated apoptosis in normal human fibroblasts. Oncogene 20: 3629-3640
73. Stoppler H, Stoppler MC, Johnson E, Simbulan-Rosenthal CM, Smulson ME, Iyer S, Rosenthal DS and Schlegel R (1998) The E7 protein of human papillomavirus type 16 sensitizes primary human keratinocytes to apoptosis. Oncogene 17: 1207-1214
74. Van Antwerp DJ, Martin SJ, Verma IM and Green DR (1998) Inhibition of TNF-induced apoptosis by NF-kappa B. Trends Cell Biol. 8: 107-111
75. Liston P, Young SS, Mackenzie AE and Korneluk RG (1997) Life and death decisions: The role of the IAPs in modulating programmed cell death. Apoptosis 2: 423-441
76. Bhardwaj A and Aggarwal BB (2003) Receptor-mediated choreography of life and death. J. Clin. Immunol. 23: 317-332
77. Lichtenstein DL, Toth K, Doronin K, Tollefson AE and Wold WS (2004) Functions and mechanisms of action of the adenovirus E3 proteins. Int. Rev. Immunol. 23: 75-111
78. Mahr JA and Gooding LR (1999) Immune evasion by adenoviruses. Immunol. Rev. 168: 121-130
79. McNees AL and Gooding LR (2002) Adenoviral inhibitors of apoptotic cell death. Virus Res. 88: 87-101
80. Duerksen-Hughes PJ, Wold WS and Gooding LR (1989) Adenovirus E1A renders infected cells sensitive to cytolysis by tumor necrosis factor. J. Immunol. 143: 4193-4200
81. Duerksen-Hughes PJ, Hermiston TW, Wold WS and Gooding LR (1991) The amino-terminal portion of CD1 of the adenovirus E1A proteins is required to induce susceptibility to tumor necrosis factor cytolysis in adenovirus-infected mouse cells. J. Virol. 65: 1236-1244
82. Carrasco RA, Stamm NB and Patel BKR (2003) One-step cellular caspase 3/7 assay. BioTechniques 34: 1064-1067